Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
Icosavax, Inc.
This is a randomized, modified double-blind, active controlled study to characterize the immunogenicity and safety of IVX-A12. Approximately 140 participants will be randomized in a 1:1 ratio to receive IVX-A12 (approximately 70) or licensed respiratory syncytial virus (RSV) vaccine (AREXVY) (approximately 70). The study is planned to be conducted at approximately 5 sites in the United States. The duration of each participant's involvement in the study will be approximately 6 months following administration of study vaccination.
Age
60–any
Sex
ALL
Healthy volunteers
Accepted